Our Current Clinical Trials

We’re actively recruiting patients to participate in clinical trials to evaluate our therapeutic candidates. If you believe you or a loved one might be a good candidate for our trials, we encourage you to reach out directly via the link below.

Expanded Access Policy
Inbrx 109


Our Tetravalent DR5 Agonist

INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

The Phase 1 trial for INBRX-109 is currently enrolling combination treatment cohorts in pancreatic adenocarcinoma, malignant pleural mesothelioma, Ewing sarcoma, and colorectal cancer.

The Phase 2 trial for INBRX-109 is currently enrolling patients with unresectable or metastatic conventional chondrosarcoma.

Learn more Phase 1 Trial Phase 2 Trial
Inbrx 106


Our Hexavalent OX40 Agonist

INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40, which is currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Parts 2 and 4, single agent dose expansion and dose expansion in combination with Keytruda, are currently enrolling in the following tumor types:

  • Solid Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Melanoma
  • Head and Neck Cancer
  • Gastric Cancer (GIST)
  • Renal Cell Carcinoma (RCC)
  • Urothelial Carcinoma
Learn more clinicaltrials.gov